PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2786632-0 1989 Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Cholecalciferol 107-117 bone gamma-carboxyglutamate protein Homo sapiens 31-42 2559250-0 1989 Effect of vitamin D3 administration on serum 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and osteocalcin in vitamin D-deficient elderly people. Cholecalciferol 10-20 bone gamma-carboxyglutamate protein Homo sapiens 96-107 32831908-0 2020 Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Cholecalciferol 40-42 bone gamma-carboxyglutamate protein Homo sapiens 71-82 2843573-0 1988 Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Cholecalciferol 18-28 bone gamma-carboxyglutamate protein Homo sapiens 66-77 2843573-7 1988 In idiopathic hypoparathyroidism, the active vitamin D3 increased serum osteocalcin without PTH. Cholecalciferol 45-55 bone gamma-carboxyglutamate protein Homo sapiens 72-83 2843573-8 1988 In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin. Cholecalciferol 97-107 bone gamma-carboxyglutamate protein Homo sapiens 117-128 32474936-8 2021 RESULTS: The vitamin D3 -induced increase of osteocalcin and osteopontin expression was significantly decreased in the presence of standard PgLPS and Pam3CSK4, which was not observed by ultrapure PgLPS. Cholecalciferol 13-23 bone gamma-carboxyglutamate protein Homo sapiens 45-56 32831908-2 2020 The objective of this study was to evaluate the effect of vitamin D3 and vitamin K2 supplements alone or in combination on osteocalcin levels and metabolic parameters in patients with T2DM. Cholecalciferol 58-68 bone gamma-carboxyglutamate protein Homo sapiens 123-134 32831908-10 2020 Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492. Cholecalciferol 23-33 bone gamma-carboxyglutamate protein Homo sapiens 100-111 32831908-10 2020 Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492. Cholecalciferol 23-33 bone gamma-carboxyglutamate protein Homo sapiens 156-167 26232635-1 2016 Recently, we found that 2alpha-[2-(tetrazol-2-yl)ethyl]-1alpha,25-dihydroxyvitamin D3 showed higher osteocalcin promoter transactivation activity in human osteosarcoma (HOS) cells and a greater therapeutic effect in ovariectomized (OVX) rats in vivo than those of active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 75-85 bone gamma-carboxyglutamate protein Homo sapiens 100-111 30678899-5 2019 Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days. Cholecalciferol 46-56 bone gamma-carboxyglutamate protein Homo sapiens 93-98 21105150-0 2010 A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3. Cholecalciferol 143-153 bone gamma-carboxyglutamate protein Homo sapiens 59-70 27542236-4 2016 The main objective was to investigate if intake of vitamin D3 enriched salmon or vitamin D3 tablets decreased bone biomarkers (urinary N-telopeptides, deoxypyridinoline, serum bone-specific alkaline phosphatase, and osteocalcin) compared to a low vitamin D3 intake. Cholecalciferol 51-61 bone gamma-carboxyglutamate protein Homo sapiens 216-227 25495336-5 2015 RESULTS: Treatment with 30 ng/mL of vitamin D3, corresponding to an optimal plasma concentration of vitamin D, for 24 h had no effect on PDL cell number and morphology but increased PDL cell osteopontin and osteocalcin mRNA expression by about 70 and 40%, respectively, and, moreover, treatment with vitamin D3 for 48 h enhanced PDL cell alkaline phosphatase activity by about two times showing that vitamin D3 exerts pro-osteogenic effects in human PDL cells. Cholecalciferol 36-46 bone gamma-carboxyglutamate protein Homo sapiens 207-218 25538061-0 2015 Identification of two populations of osteoarthritic osteoblasts according to the 1,25[OH]2 vitamin D3 potency to stimulate osteocalcin. Cholecalciferol 91-101 bone gamma-carboxyglutamate protein Homo sapiens 123-134 24911063-7 2014 These cells responded to treatment with activated vitamin D3 by upregulating OCN. Cholecalciferol 50-60 bone gamma-carboxyglutamate protein Homo sapiens 77-80 17956020-3 2007 In the bones treated with vitamin D3 plus vitamin K2, osteocalcin production and the ratio of the mineralization of osteoblasts were increased. Cholecalciferol 26-36 bone gamma-carboxyglutamate protein Homo sapiens 54-65 20664979-4 2010 The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts. Cholecalciferol 74-84 bone gamma-carboxyglutamate protein Homo sapiens 123-134 18683889-6 2009 Vitamin D(3) was also shown to induce the expression of the osteoblast-specific markers, alkaline phosphatase and osteocalcin, in a dose-dependent manner in human dermal fibroblasts. Cholecalciferol 0-12 bone gamma-carboxyglutamate protein Homo sapiens 114-125 17326835-4 2007 Osteoblasts were incubated in the presence of vitamin D3 (50 nM), which is an inducer of osteocalcin, encoded by an osteoblast terminal differentiation gene. Cholecalciferol 46-56 bone gamma-carboxyglutamate protein Homo sapiens 89-100 17326835-11 2007 The vitamin D3 induced osteocalcin was strongly inhibited in a dose-dependent manner in the presence of gal-3, at both the mRNA and protein levels. Cholecalciferol 4-14 bone gamma-carboxyglutamate protein Homo sapiens 23-34 16844314-8 2006 We present an example from our own studies by showing that vitamin D3 has the potential to de-methylate the osteocalcin-promoter in MG63 osteosarcoma cells. Cholecalciferol 59-69 bone gamma-carboxyglutamate protein Homo sapiens 108-119 16772287-2 2006 Two nuclease-hypersensitive sites span the key regulatory elements that control basal tissue-specific and vitamin D3-enhanced OC gene transcription. Cholecalciferol 106-116 bone gamma-carboxyglutamate protein Homo sapiens 126-128 16772287-5 2006 This interaction results in inhibition of both basal and vitamin D3-enhanced OC gene transcription and a marked decrease in nuclease hypersensitivity. Cholecalciferol 57-67 bone gamma-carboxyglutamate protein Homo sapiens 77-79 12892157-3 2003 This study aimed to determine whether supplementation with vitamin D3 to healthy children during the winter affects bone turnover in healthy children measured by serum osteocalcin, PICP, PINP or ICTP. Cholecalciferol 59-69 bone gamma-carboxyglutamate protein Homo sapiens 168-179 16091841-3 2005 Osteocalcin production was evaluated by cultured cells in neridronate 10(-4) M and 10(-6) M, both under basal conditions and after vitamin D3 stimulation. Cholecalciferol 131-141 bone gamma-carboxyglutamate protein Homo sapiens 0-11 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 52-63 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 203-214 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 203-214 15801068-0 2004 Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Cholecalciferol 85-95 bone gamma-carboxyglutamate protein Homo sapiens 0-11 15801068-3 2004 In this study we correlated osteocalcin production from human osteoblasts isolated from healthy and osteoarthritic subjects to the degree of cartilage damage, before and after stimulation with 1,25(OH)2-vitamin D3, the active metabolite of vitamin D3. Cholecalciferol 203-213 bone gamma-carboxyglutamate protein Homo sapiens 28-39 15801068-5 2004 We determined the osteocalcin production in normal and osteoarthritic osteoblasts from maximal and minimal cartilage damage areas both under basal conditions and after vitamin D3 stimulation. Cholecalciferol 168-178 bone gamma-carboxyglutamate protein Homo sapiens 18-29 15801068-8 2004 The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 151-162 15801068-8 2004 The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones. Cholecalciferol 120-130 bone gamma-carboxyglutamate protein Homo sapiens 151-162 15801068-9 2004 Thus, after vitamin D3 stimulation, a significant increase in osteocalcin production by maximally damaged osteoblasts compared to the minimally damaged ones was observed. Cholecalciferol 12-22 bone gamma-carboxyglutamate protein Homo sapiens 62-73 15375610-9 2004 The complete human Osteocalcin promoter and the bone-sialoprotein promoter were partially induced by vitamin D3 or C respectively while the pAd.3r-luc activity could be shut down by doxycyclin. Cholecalciferol 101-111 bone gamma-carboxyglutamate protein Homo sapiens 19-30 12697832-4 2003 Therefore, we addressed p300 control of basal and vitamin D(3)-enhanced activity of the OC promoter. Cholecalciferol 50-62 bone gamma-carboxyglutamate protein Homo sapiens 88-90 12697832-5 2003 We find that transient overexpression of p300 results in a significant dose-dependent increase of both basal and vitamin D(3)-stimulated OC gene activity. Cholecalciferol 113-125 bone gamma-carboxyglutamate protein Homo sapiens 137-139 10203416-10 1999 In contrast, treatment with vit D3 induced a marked increase of ALP and OC transcripts. Cholecalciferol 28-34 bone gamma-carboxyglutamate protein Homo sapiens 72-74 11814331-2 2002 To explain this clinical observation, we investigated the mechanism of action of lead on vitamin D3-dependent osteocalcin production. Cholecalciferol 89-99 bone gamma-carboxyglutamate protein Homo sapiens 110-121 11805636-13 2002 CONCLUSIONS: Posterior longitudinal ligament cells from the three North American white patients with ossification of the posterior longitudinal ligament, when cultured in vitro, synthesized osteocalcin on vitamin D3 priming, confirming their osteoblastic phenotype, whereas posterior longitudinal ligament cells from four white patients with isolated spondylosis did not. Cholecalciferol 205-215 bone gamma-carboxyglutamate protein Homo sapiens 190-201 11814331-5 2002 Treatment of ROS cells with Go6976, an inhibitor of PKC alpha and beta isozymes, produced similar effects as lead on vitamin D3-dependent osteocalcin production, while activation of PKC by phorbol-12-myristate-13-acetate (TPA) did not reverse or mimic this effect of lead. Cholecalciferol 117-127 bone gamma-carboxyglutamate protein Homo sapiens 138-149 12112004-0 2002 Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. Cholecalciferol 74-84 bone gamma-carboxyglutamate protein Homo sapiens 43-54 9677345-7 1998 Moreover, vitamin D3 enhanced calbindin-D28K synthesis as well as OC synthesis and alkaline phosphatase activity. Cholecalciferol 10-20 bone gamma-carboxyglutamate protein Homo sapiens 66-68 9705080-4 1998 The integrity of OLCs was confirmed by their ability to produce alkaline phosphatase and osteocalcin in response to vitamin D3 and also by their ability to deposit mineral. Cholecalciferol 116-126 bone gamma-carboxyglutamate protein Homo sapiens 89-100 1843267-2 1991 The administration of active vitamin D3 gradually increased the serum BGP to more than 3 times the original level by the 8th week. Cholecalciferol 29-39 bone gamma-carboxyglutamate protein Homo sapiens 70-73 9430985-0 1997 [Serum bone Gla-protein increases following short-term oral administration of active vitamin D3 in the elderly with vitamin D deficiency]. Cholecalciferol 85-95 bone gamma-carboxyglutamate protein Homo sapiens 7-23 9430985-2 1997 It is well known that serum BGP levels increase after oral administration of active vitamin D3 in postmenopausal women and patients with chronic renal failure before dialysis. Cholecalciferol 84-94 bone gamma-carboxyglutamate protein Homo sapiens 28-31 9430985-3 1997 These findings indicate that active vitamin D3 increases the BGP production by osteoblasts. Cholecalciferol 36-46 bone gamma-carboxyglutamate protein Homo sapiens 61-64 7484280-3 1995 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), an active form of vitamin D3, stimulated OC secretion from the human osteosarcoma cell line MG-63 in a dose-dependent manner. Cholecalciferol 14-24 bone gamma-carboxyglutamate protein Homo sapiens 81-83 8253854-3 1993 Similar to controls, OI bone cells produced predominantly collagen type I with traces of collagen types III and V. The 1,25(OH)2 vitamin D3-stimulated synthesis of osteocalcin, a specific osteoblastic marker protein, was similar in OI bone cells and age-matched controls. Cholecalciferol 129-139 bone gamma-carboxyglutamate protein Homo sapiens 164-175 9457545-7 1998 As indicated by increased alkaline phosphatase-specific activity, increased cell-surface and matrix-associated protein, and 1.25 (OH2) vitamin D3-stimulated osteocalcin production, a more differentiated osteoblast-like phenotype was observed on the sintered HA surfaces compared to the as-received HA and calcined HA surfaces. Cholecalciferol 135-145 bone gamma-carboxyglutamate protein Homo sapiens 157-168 9333117-6 1997 To investigate further the mechanism for the apparent species difference in vitamin D3 induction of mouse and human osteocalcin, we examined the effect of 1,25(OH)2D3 in an MC3T3-E1 cell line (MC4) containing a stably integrated 3900 bp osteocalcin promoter-luciferase construct. Cholecalciferol 76-86 bone gamma-carboxyglutamate protein Homo sapiens 116-127 8895322-10 1996 Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced > 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes. Cholecalciferol 0-10 bone gamma-carboxyglutamate protein Homo sapiens 26-37 8895322-10 1996 Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced > 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes. Cholecalciferol 0-10 bone gamma-carboxyglutamate protein Homo sapiens 286-297 1843267-3 1991 At the 12th week after starting the active vitamin D3 therapy, mean BGP was about twice the original level, which was about half the maximum level at the 8th week. Cholecalciferol 43-53 bone gamma-carboxyglutamate protein Homo sapiens 68-71 1843267-7 1991 These data suggest that BGP was increased through direct stimulation of osteoblasts by the active vitamin D3, and the increase was not due to deterioration of secondary hyperparathyroidism. Cholecalciferol 98-108 bone gamma-carboxyglutamate protein Homo sapiens 24-27 1843267-8 1991 The reduction of the increase in the BGP level at the 12th week with insignificant biochemical changes suggest that activation of osteoblasts by vitamin D3 may be transient. Cholecalciferol 145-155 bone gamma-carboxyglutamate protein Homo sapiens 37-40 1843267-9 1991 In conclusion, intermittent active vitamin D3 increases serum BGP, without deterioration of major biochemical changes even in patients with moderate to severe secondary hyperparathyroidism, although the increase may be transient. Cholecalciferol 35-45 bone gamma-carboxyglutamate protein Homo sapiens 62-65 1843267-10 1991 These facts suggest that the serum BGP of hemodialysis patients is controlled at least in part by active vitamin D3. Cholecalciferol 105-115 bone gamma-carboxyglutamate protein Homo sapiens 35-38